医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hitachi Chemical Developed Novel Molecular Testing System for Personalized Medicine – Novel mRNA Quantitative Assay for Biomarker Discovery and Prediction of Drug Efficacy

2012年11月15日 PM09:25
このエントリーをはてなブックマークに追加


 

TOKYO

Hitachi Chemical Co., Ltd. (TOKYO:4217)(Head Office: Tokyo; President and CEO: Kazuyuki Tanaka; Capital: 15.5 billion yen; hereinafter referred to as “Hitachi Chemical”), in the field of life sciences, developed a novel mRNA quantitative assay called “Hem(A)+ System”i. This is a simple, high-throughput, reproducible method, that offers a wide range of applications in clinical biomarker discovery and molecular testing to target personalized medicineii.

In today’s aging society, maintaining good health and improving quality of life while reducing healthcare costs is a key challenge. We are facing the growing need for medical treatments with high efficacy and minimum adverse effects. As a result, “personalized medicine” is receiving significant attention as an approach to meet such needs.

By targeting personalized medicine, Hitachi Chemical developed the “Hem(A)+ System,” to address this need for improved medical treatments. This system can extract and quantify leukocyte-derived mRNA from a very small amount of whole blood (0.05 mL). It employs simple filtration to capture leukocyte prior to extraction and purification of mRNA. This eliminates interference by a large amount of red blood cells in whole blood, and enables sensitive detection of the changes in mRNA levels. Also, the system adopts a 96-well microplate format, making it suitable for simultaneous processing of multiple samples. The best feature of this system is that it simulates the drug response of an individual in a test tube by using whole blood samples stimulated with the drug. This system successfully brought a new “ex vivo” concept, which measures in vivo response in an in vitro assay, to practice and makes it possible to predict drug efficacy.

With this system, Hitachi Chemical plans to conduct contract test services for pharmaceutical companies to find novel biomarkers and select subjects for clinical trials by predicting drug efficacy, and eventually aims to have this system as a companion diagnosticiii.

We are actively conducting collaborative research in a wide range of clinical fields in Japan and the US. We had poster presentations at the SITC 27th Annual Meetingiv held in the late October, on predictive markers for the efficacy of a breast cancer drug and dendritic cell vaccine therapy for cancersv. We will also have a poster presentation at the 2012 ASH Annual Meeting and Expositionvi scheduled in early December about the predictive markers of effect of a multiple myeloma drug and adverse effect.

< Reference >

About Hitachi Chemical:
Hitachi Chemical is a chemical manufacturing company headquartered in Tokyo. The company has 16,713 employees, a sales volume of 473.1 billion yen (fiscal 2011, consolidated), with many products holding top market share. Its products are aimed at a wide range of materials and parts, including functional materials and high-tech parts/system segments. The company is also focusing its efforts on “life sciences” as one of four core business areas, selling products such as OPTIGEN Systems for allergy diagnosis and Hitachi Clinical Analyzers for clinical chemistry testing.

     

i

  “Hem(A)+ System”: Assay system developed by Hitachi Chemical Research Center, Inc. (Location: California, President: Bunichiro Nakajima; abbreviated to “HCR”), a US subsidiary of Hitachi Chemical.

ii

“Personalized medicine”: Medical model to provide the best prevention and treatment optimized for each person. It often refers to “the right treatment for the right individual at the right time”.

iii

“Companion Diagnostics”: Diagnostic examination to select patients who are likely to benefit from certain medication by predicting efficacy and adverse reactions of drugs. The naming is from “diagnostics used as a companion to drugs.”

iv

“SITC 27th Annual Meeting”: Annual meeting of the Society for Immunotherapy of Cancer: Held in North Bethesda, Maryland, USA, October 26-28, 2012. SITC 27th Annual Meeting: http://www.sitcancer.org/2012

v

“Dendritic cell vaccine therapy for cancers”: An immunotherapy for advanced cancers.

vi

“2012 ASH Annual Meeting”: Annual Meeting of the American Society of Hematology”: To be held in Atlanta, Georgia, USA, December 8-11, 2012. 2012 ASH Annual Meeting and Exposition: http://www.hematology.org/meetings/annual-meeting/

CONTACT

Hitachi Chemical Research Center, Inc.
Wakako Matsumoto,
949-725-2721
Manager Business Development

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent